Qualigens Pharma Private Limited

Qualigens Pharma Private Limited, established on October 10, 2013, is a privately held pharmaceutical company headquartered in Khalapur, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24100MH2013PTC249071. As of the latest available data, Qualigens Pharma has an authorized capital of ₹2.00 crore and a paid-up capital of ₹1.55 crore. The company employs approximately 226 professionals, reflecting its commitment to quality and operational excellence.

Qualigens Pharma specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing facility is situated in a serene, dust-free, and pollution-free environment in Khopoli, Maharashtra, ensuring optimal conditions for pharmaceutical production. This facility has been accredited by several regulatory agencies, including EU-GMP, SAHPRA, Russian GMP, and WHO-GMP, underscoring its adherence to international quality standards.

Qualigens Pharma's state-of-the-art manufacturing facility in Khopoli, Maharashtra, is designed to meet current Good Manufacturing Practice (cGMP) requirements. The plant boasts an annual capacity of over 4 billion tablets and 600 million capsules, catering to both niche complex molecules and high-volume generic products. The facility is equipped with high-end local and imported machinery to ensure quality by design (QbD) and defect-free products. Additionally, the plant has been accredited by several regulatory agencies, including EU-GMP, SAHPRA, Russian GMP, and WHO-GMP, reflecting its commitment to maintaining international quality standards.

The leadership team at Qualigens Pharma Private Limited comprises professionals with extensive experience in the pharmaceutical sector. Ajit Jain serves as a Director, bringing his expertise to the company's strategic direction. Aayush Jain, also a Director, holds qualifications in Chartered Accountancy (CA) and an MBA, contributing to the company's financial and operational strategies. Ankit Suresh Paharia, another Director, is a Chartered Accountant, adding to the financial acumen of the leadership team. These leaders, with over 30 years of combined experience, drive the company's mission to develop quality-assured generic and branded pharmaceutical products.

Qualigens Pharma Private Limited has established a presence in several regulated markets, including the European Union (EU), South Africa, Russia, and other international markets. The company's manufacturing facility has been accredited by multiple regulatory agencies, such as EU-GMP, SAHPRA, Russian GMP, and WHO-GMP, indicating compliance with international quality standards. These accreditations facilitate market access and underscore the company's commitment to maintaining high-quality manufacturing practices.

In the United States, the company has achieved FDA certification, further expanding its reach in regulated markets. This certification reflects Qualigens Pharma's adherence to stringent manufacturing standards and its dedication to delivering quality pharmaceutical products globally.

Qualigens Pharma Private Limited has successfully established its presence in emerging markets, particularly in Africa and Latin America. The company's manufacturing facility holds WHO-GMP certification, which is essential for accessing these markets. This certification enables Qualigens Pharma to supply quality-assured pharmaceutical products to regions where WHO prequalification is a prerequisite for market entry.

The company's strategic focus on emerging markets aligns with its mission to become a world pioneer in the healthcare segment by developing a wide range of quality-assured generic and branded pharmaceutical products. By leveraging its manufacturing capabilities and regulatory certifications, Qualigens Pharma aims to expand its footprint in these regions, contributing to global healthcare needs.

Qualigens Pharma Private Limited demonstrates a diversified geographic strategy by establishing a presence in both regulated and emerging markets. The company's accreditations, including EU-GMP, SAHPRA, Russian GMP, and WHO-GMP, facilitate market access across various regions. This strategic diversification mitigates concentration risk and positions the company to capitalize on growth opportunities in different markets. By catering to both high-volume generic products and niche complex molecules, Qualigens Pharma aligns its product offerings with the specific demands of each market segment.

The company's focus on emerging markets, supported by WHO-GMP certification, further enhances its strategic positioning. This approach not only broadens the company's market reach but also underscores its commitment to providing quality pharmaceutical products to diverse populations. Overall, Qualigens Pharma's geographic strategy reflects a balanced approach to market expansion, risk management, and alignment with global healthcare needs.

Qualigens Pharma Private Limited has achieved FDA certification, indicating compliance with the stringent manufacturing standards set by the U.S. Food and Drug Administration. This certification reflects the company's commitment to quality and safety in pharmaceutical production. The FDA certification enhances the company's credibility and facilitates access to the U.S. market, a key destination for pharmaceutical exports.

The FDA certification process involves rigorous inspections and evaluations to ensure adherence to current Good Manufacturing Practices (cGMP). By obtaining this certification, Qualigens Pharma demonstrates its capability to meet the high standards required for pharmaceutical manufacturing in the United States. This achievement positions the company favorably for partnerships and collaborations with U.S.-based pharmaceutical companies and distributors.

Qualigens Pharma Private Limited holds WHO-GMP certification, which is essential for accessing markets where WHO prequalification is a prerequisite for market entry. This certification underscores the company's commitment to maintaining high-quality manufacturing practices and ensures that its products meet international standards.

Additionally, the company's manufacturing facility is accredited with EU-GMP certification, reflecting compliance with the European Union's stringent manufacturing standards. This accreditation facilitates market access within the EU and demonstrates the company's dedication to quality and safety in pharmaceutical production.

Qualigens Pharma Private Limited operates in compliance with the regulations set forth by the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility holds necessary licenses and approvals from the CDSCO, ensuring adherence to national standards for pharmaceutical manufacturing. These approvals are crucial for the company's operations and for maintaining the quality and safety of its products.

The company's commitment to regulatory compliance is further demonstrated by its adherence to state drug controller approvals and export No Objection Certificates (NOCs). These certifications are essential for the legal export of pharmaceutical products from India and reflect the company's dedication to maintaining high standards in all aspects of its operations.

As of the latest available information, there are no publicly disclosed Form 483 observations, warning letters, or import alerts associated with Qualigens Pharma Private Limited. This absence indicates that the company has maintained a clean regulatory record, reflecting its commitment to adhering to the standards set by regulatory bodies such as the FDA and WHO. Maintaining a clean regulatory record is essential for sustaining market access and upholding the company's reputation in the pharmaceutical industry.

In the pharmaceutical industry, Qualigens Pharma Private Limited faces competition from both domestic and international companies operating in similar therapeutic categories. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, places it in competition with other manufacturers offering similar products. However, Qualigens Pharma's commitment to quality, as evidenced by its various certifications, provides a competitive edge in the market.

The company's strategic focus on both regulated and emerging markets allows it to tap into diverse customer bases, mitigating risks associated with market concentration. By leveraging its manufacturing capabilities and regulatory certifications, Qualigens Pharma positions itself as a competitive player in the global pharmaceutical market.

Qualigens Pharma Private Limited distinguishes itself through its state-of-the-art manufacturing facility, which is accredited by multiple regulatory agencies, including EU-GMP, SAHPRA, Russian GMP, and WHO-GMP. This diverse range of certifications underscores the company's commitment to maintaining high-quality manufacturing practices and facilitates access to various international markets.

The company's focus on both niche complex molecules and high-volume generic products allows it to cater to a broad spectrum of market needs. Additionally, Qualigens